OTCMKTS:GMXAYGENMAB A/S/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GENMAB A/S/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range$18.38MA: $20.35▼$25.2252-Week Range N/AVolume300,050 shsAverage Volume48,553 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartHeadlinesSocial Media Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for GENMAB A/S/S. Previous Next 2.6 Community Rank Outperform VotesGENMAB A/S/S has received 59 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGENMAB A/S/S has received 54 “underperform” votes. (Add your “underperform” vote.)Community SentimentGENMAB A/S/S has received 52.21% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about GENMAB A/S/S and other stocks. Vote “Outperform” if you believe GMXAY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GMXAY will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGENMAB A/S/S does not currently pay a dividend.Dividend GrowthGENMAB A/S/S does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GENMAB A/S/S insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.52 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:GMXAY Previous Symbol CUSIPN/A CIKN/A Webhttp://www.genmab.com/ Phone45 70 20 27 28Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees377 Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive GMXAY News and Ratings via Email Sign-up to receive the latest news and ratings for GMXAY and its competitors with MarketBeat's FREE daily newsletter. OTC:GMXAY Rates by TradingView GENMAB A/S/S (OTCMKTS:GMXAY) Frequently Asked Questions Has GENMAB A/S/S been receiving favorable news coverage? News articles about GMXAY stock have trended very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GENMAB A/S/S earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutGENMAB A/S/S. Who are some of GENMAB A/S/S's key competitors? Some companies that are related to GENMAB A/S/S include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Admedus (AHZ), Almirall (LBTSF), Apotheca Biosciences (CBDC), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Baudax Bio (BXRXV), BerGenBio ASA (BRRGF), Biocure Technology (CURE), Canada House Wellness Group (CHV), Cannabics Pharmaceuticals (CNBX), CannaRoyalty (ORHOF) and Cardiome Pharma (COM). What other stocks do shareholders of GENMAB A/S/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other GENMAB A/S/S investors own include Genmab A/S (GNMSF), ZTO Express (Cayman) (ZTO), Teva Pharmaceutical Industries (TEVA) and GALAPAGOS NV/S (GLPG). Who are GENMAB A/S/S's key executives? GENMAB A/S/S's management team includes the following people: Dr. Jan G. J. van de Winkel, Co-Founder, Pres & CEO (Age 58)Mr. David A. Eatwell, Exec. VP & CFO (Age 58)Mr. Peter Storm Kristensen, Associate Director of Legal & Non-Independent Director (Age 44)Mr. Rick Hibbert, Associate Director of Protein Production & Chemistry and Non-Independent Director (Age 39)Dr. Judith V. Klimovsky, Exec. VP & Chief Devel. Officer (Age 61) What is GENMAB A/S/S's stock symbol? GENMAB A/S/S trades on the OTCMKTS under the ticker symbol "GMXAY." How do I buy shares of GENMAB A/S/S? Shares of GMXAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is GENMAB A/S/S's official website? The official website for GENMAB A/S/S is http://www.genmab.com/. How can I contact GENMAB A/S/S? The company can be reached via phone at 45 70 20 27 28. This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: Sell-Side Analysts
